Serve as a consumer reviewer for DOD grants!
The DOD has asked FCF to help to recruit FLC community members to serve as consumer reviewers for this fall’s CDMRP grant review process. This …
Jaime Crook joins Patient & Caregiver Advisory Board
FCF is pleased to announce that Jaime Crook has joined our Patient & Caregiver Advisory Board. This group of highly committed volunteers meet and share their perspectives to help improve FCF’s research, educational, and support programs to better serve patients and families fighting this awful disease. When she was six years old, Jamie regularly complained …
New Minnesota legislation to be named in Amara Strande’s honor
In a news conference on May 9, Minnesota lawmakers and advocates celebrated an emerging deal which would ban would ban the non-essential use of PFAS (perfluoroalkyl or polyfluoroalkyl substances) starting in 2025. PFAS, so called “forever chemicals”, are hard to break down. Studies indicate that exposure to these chemicals could increase a person’s risk of …
New study of FLC organoids published
In a study funded by FCF, scientists at the Princess Máxima Center for pediatric oncology and the Hubrecht Institute in the Netherlands have revealed new insights into the features of fibrolamellar carcinoma (FLC). Their findings, published this week in Nature Communications, may help in developing new drug therapies in the future. The study, led by …
Collaboration and confidentiality: FCF’s 2023 Scientific Summit
This week, approximately 70 cancer specialists from U.S. and international research institutions gathered in Greenwich, Connecticut to collaborate share research information about fibrolamellar carcinoma (FLC). For the 5th time, the Fibrolamellar Cancer Foundation sponsored an international symposium designed to bring together the community of researchers investigating FLC, foster deeper collaboration among those teams, and accelerate …
Team at Fred Hutch awarded 2-year grant
FCF is pleased to announce that Dr. Taran Gujral of the Fred Hutchinson Cancer Center in Seattle, Washington has been awarded a two-year grant. Dr. Gujral studies both tumor cells and their microenvironment. His lab has been developing new patient-derived xenograft (PDX) and cell culture models from human FLC tumors to facilitate the search for …
Grant awarded to Dr. Julien Sage of Stanford University
FCF is pleased to announce that we have awarded Dr. Julien Sage of Stanford University a one-year grant entitled “Development of pre- clinical murine models for fibrolamellar hepatocellular carcinoma”. Dr. Sage is recognized as a world leader in using genome-editing to develop and study genetically-engineered mouse models for human cancers, including lung cancer, pancreatic cancer, …
Scholarship opportunity for rare disease patients
The EveryLife Foundation has announced a scholarship opportunity for rare disease patients. If you are 17 or older and a resident of the United States who has been diagnosed as having any form of rare disease, you are invited to apply for the #RAREis Scholarship Fund. Under this program, the EveryLife Foundation plans to award up to seventy …
Newly published study points to higher incidence rate for FLC
A new study, recently published in Nature Precision Oncology, indicates that the incidence rate of fibrolamellar carcinoma (FLC) may be significantly higher than commonly cited statistics for the disease. The study, led by Dr. Travis Zack, Dr. John Gordan and Kurt Losert, combined a detailed analysis of electronic medical records (EMR) from a healthcare system …